CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Prasugrel +1 moredrug
Likely dose
Prasugrel 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01852214
NCT01852214N/ACompleted
CompareCT.gov

A Pharmacodynamic Comparison of Prasugrel vs. Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

University of Florida·interventional·Posted May 13, 2013·Updated Oct 17, 2016

In Brief

A clinical study evaluating Prasugrel and Ticagrelor for Diabetes Mellitus and Coronary Artery Disease. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Patients with diabetes mellitus (DM) have an increased risk of adverse atherothrombotic events. This may be in part attributed to the fact that these patients have reduced response to oral antiplatelet medications, in particular the P2Y12 receptor inhibitor clopidogrel, used for secondary prevention of ischemic events. Prasugrel and ticagrelor are recently approved P2Y12 receptor inhibitors which, compared with clopidogrel, have more potent antiplatelet effects. Head-to-head comparisons between the two drugs are lacking.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Coronary Artery Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 13, 2013
Enrollment StartFeb 1, 2013
Primary CompletionJul 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 13.1 years ago

Interventions

Prasugreldrug

Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose

Ticagrelordrug

Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose